









Markets
/
Stocks
/
nasdaq-elan
/

Elanco Animal Health Inc

ELAN

25.500USD

+0.600+2.41%

Close 03/25, 16:00（ET）Quotes delayed by 15 min

9.08BMarket Cap

LossP/E TTM



Elanco Animal Health Inc

25.500

+0.600+2.41%

Overview Financials Analysis Company

TradingKey Stock Score

Overall Financial Health

Valuation Dimensions

Earnings Forecast

Price Momentum

Institutional Confidence

Risk Assessment

Peer Comparison

Overview

Financials

Analysis

Company

TradingKey Stock Score

Overall Financial Health

Valuation Dimensions

Earnings Forecast

Price Momentum

Institutional Confidence

Risk Assessment

Peer Comparison

TradingKey Stock Score of Elanco Animal Health Inc

Currency: USD Updated: 2026-03-24

Key Insights

Elanco Animal Health Inc's fundamentals are relatively stable, with an industry-leading ESG disclosure.and its growth potential is high.Its valuation is considered fairly valued, ranking 19 out of 157 in the Pharmaceuticals industry.Institutional ownership is very high.Over the past month, multiple analysts have rated it as Buy, with the highest price target at 29.58.In the medium term, the stock price is expected to trend up.Despite a weak stock market performance over the past month, the company shows strong fundamentals and technicals.The stock price is trading sideways between the support and resistance levels, making it suitable for range-bound swing trading.

Elanco Animal Health Inc's Score

Industry at a Glance

Industry Ranking

19 / 157

Overall Ranking

76 / 4547

Industry

Pharmaceuticals

Support & Resistance

Relevant data have not been disclosed by the company yet.

Score Analysis

Current score

Previous score

Media Coverage

Last 24 hours

Coverage Level

Very Low

Very High

Neutral

Elanco Animal Health Inc Highlights

StrengthsRisks

Elanco Animal Health Incorporated is an animal health company delivering products and services to prevent and treat disease in farm animals and pets. The Company's product portfolio is sold in more than 90 countries and serves animals across many species, primarily dogs and cats (collectively, pet health) and cattle, poultry, swine, and sheep (collectively, farm animal). It has a diverse portfolio of products marketed under approximately 200 brands, including products for both pets and farm animals. The Company's global pet health portfolio is focused on parasiticides, vaccines and therapeutics. Its pet health products include Advantage Family, Atopica, Credelio Family, Drontal Family, Galliprant, Interceptor Plus, Milbemax, Onsior, Seresto, Trifexis, and TruCan. Its farm animal products include AviPro, Baytril, Catosal, Denagard, Experior, Hemicell, Maxiban/Monteban, Pulmotil, Rumensin, and Surmax. Its customers include consultants, veterinarians, farm animal producers and resellers.

Turnaround to Loss

The company's performance has turned to a loss, with the latest annual loss of USD .

Undervalued

The company’s latest PE is -53.28, at a low 3-year percentile range.

Institutional Buying

The latest institutional holdings are 577.24M shares, increasing 0.01% quarter-over-quarter.

Held by CI Select Canadian Equity Fund

Star Investor CI Select Canadian Equity Fund holds 6.39K shares of this stock.

Higher Market Activity

The company has more investor interest, with a 20-day turnover ratio of 1.06.

Analyst Rating

Based on 16 analysts

Buy

Current Rating

29.583

Target Price

+23.37%

Upside Space

Data disclaimer: Analyst ratings and target prices are provided by LSEG for informational purposes only and do not constitute investment advice.

Financial Health

Currency: USD Updated: 2026-03-24

The current financial score of Elanco Animal Health Inc is 7.31, ranking 114 out of 157 in the Pharmaceuticals industry. Its financial status is weak, and its operating efficiency is high. Its latest quarterly revenue reached 1.14B, representing a year-over-year increase of 12.16%, while its net profit experienced a year-over-year increase of 3350.00%.

Score

Industry at a Glance

Previous score

7.31

Change



Financials

5.43

Key Metrics

Cash and cash equivalents

Total assets

Total liabilities

Free cash flow

Relevant data have not been disclosed by the company yet.



Quality of Earnings

6.37

Key Metrics

Total revenue

Operating profit

Total assets

SG&A

Relevant data have not been disclosed by the company yet.



Operational Efficiency

10.00

Key Metrics

Cash flow from operating activities

Income after tax

Relevant data have not been disclosed by the company yet.



Growth Potential

7.46

Key Metrics

Cash flow from operating activities

Total revenue

Relevant data have not been disclosed by the company yet.



Shareholder Returns

7.27

Key Metrics

Free cash flow

Relevant data have not been disclosed by the company yet.

Elanco Animal Health Inc's Company Valuation

Currency: USD Updated: 2026-03-24

The current valuation score of Elanco Animal Health Inc is 7.41, ranking 70 out of 157 in the Pharmaceuticals industry. Its current P/E ratio is -53.28, which is -784.57% below the recent high of 364.72 and -302.41% above the recent low of -214.39.

Score

Industry at a Glance

Previous score

7.41

Change

Valuation Dimensions

P/E

P/B

P/S

P/CF

Industry Ranking 19/157

Relevant data have not been disclosed by the company yet.

Earnings Forecast

Currency: USD Updated: 2026-03-24

The current earnings forecast score of Elanco Animal Health Inc is 8.63, ranking 20 out of 157 in the Pharmaceuticals industry. The average price target is 25.00, with a high of 30.00 and a low of 18.00.

Score

Industry at a Glance

Previous score

8.63

Change

Support & Resistance

Relevant data have not been disclosed by the company yet.

Analyst Rating

Based on 16 analysts

Buy

Current Rating

29.583

Target Price

+21.04%

Upside Space

Strong Buy

Buy

Hold

Sell

Strong Sell

Peer Comparison

Total

Median

Average

Company name

Ratings

Analysts

Elanco Animal Health Inc

ELAN

Apple Inc

AAPL

Ge Vernova Inc

GEV

Tapestry Inc

TPR

Verisk Analytics Inc

VRSK

Avantor Inc

AVTR

...

Financial Forecasting

EPS

Revenue

Net Profit

EBIT

Relevant data have not been disclosed by the company yet.

Data disclaimer: Analyst ratings and target prices are provided by LSEG for informational purposes only and do not constitute investment advice.

Price Momentum

Currency: USD Updated: 2026-03-24

The current price momentum score of Elanco Animal Health Inc is 7.44, ranking 13 out of 157 in the Pharmaceuticals industry. Currently, the stock price is trading between the resistance level at 27.61 and the support level at 22.31, making it suitable for range-bound swing trading.

Score

Industry at a Glance

Previous score

7.30

Change

0.14

Support & Resistance

Relevant data have not been disclosed by the company yet.

Indicators



The Indicators feature provides value and direction analysis for various instruments under a selection of technical indicators, together with a technical summary.

This feature includes nine of the commonly used technical indicators: MACD, RSI, KDJ, StochRSI, ATR, CCI, WR, TRIX and MA. You may also adjust the timeframe depending on your needs.

Please note that technical analysis is only part of investment reference, and there is no absolute standard for using numerical values to assess direction. The results are for reference only, and we are not responsible for the accuracy of the indicator calculations and summaries.

Indicators

Sell(1)

Neutral(2)

Buy(3)

Indicators

Value

Direction

MACD(12,26,9)

0.265

Neutral

RSI(14)

56.722

Neutral

STOCH(KDJ)(9,3,3)

82.899

Buy

ATR(14)

1.030

High Vlolatility

CCI(14)

119.793

Buy

Williams %R

5.521

Overbought

TRIX(12,20)

-0.105

Sell

StochRSI(14)

100.000

Buy

Moving Average

Sell(0)

Neutral(0)

Buy(6)

Indicators

Value

Direction

MA5

24.788

Buy

MA10

24.297

Buy

MA20

24.465

Buy

MA50

24.665

Buy

MA100

23.472

Buy

MA200

20.347

Buy

Institutional Confidence

Currency: USD Updated: 2026-03-24

The current institutional shareholding score of Elanco Animal Health Inc is 10.00, ranking 1 out of 157 in the Pharmaceuticals industry. The latest institutional shareholding proportion is 120.43%, representing a quarter-over-quarter decrease of 1.24%. The largest institutional shareholder is Van Duyn Dodge & E. Morris Cox, holding a total of 79.08M shares, representing 15.91% of shares outstanding, with 4.73% decrease in holdings.

Score

Industry at a Glance

Previous score

10.00

Change

Institutional Shareholding

Relevant data have not been disclosed by the company yet.

Shareholder Activity

Name

Shares Held

Chg %

Dodge & Cox

Star Investors

82.76M

-0.16%

The Vanguard Group, Inc.

Star Investors

48.46M

+1.71%

PRIMECAP Management Company

Star Investors

49.96M

-3.49%

BlackRock Institutional Trust Company, N.A.

40.42M

+106.48%

Fidelity Management & Research Company LLC

50.74M

+5.18%

T. Rowe Price Investment Management, Inc.

31.51M

+61.14%

Dimensional Fund Advisors, L.P.

24.71M

+8.63%

State Street Investment Management (US)

15.25M

+67.04%

Fidelity Institutional Asset Management

14.62M

-12.17%

Black Creek Investment Management, Inc.

12.48M

-35.16%

Risk Assessment

Currency: USD Updated: 2026-03-24

The U.S. Dollar Index is currently in a neutral state, which has a neutral effect on the Pharmaceuticals domestic-focused industry. The Dollar Index (DXY) measures the value of the U.S. dollar against a basket of major currencies, including the euro, yen, pound sterling, Canadian dollar, Swedish krona, and Swiss franc. The current risk assessment score of Elanco Animal Health Inc is 7.85, ranking 33 out of 157 in the Pharmaceuticals industry. The company's beta value is 1.86. This indicates that the stock tends to outperform the index during upward trending markets but experiences larger declines during downward trending markets. with an industry-leading ESG disclosure.